Acerus Pharmaceuticals Corporation  

(Public, CVE:JV.P)   Watch this stock  
Find more results for Gregory P. Hawkins�
Feb 4 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.21
Open     -
Vol / Avg. 0.00/19,467.00
Mkt cap 1.20M
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -
Nov 4, 2015
Q3 2015 Trimel Pharmaceuticals Corp Earnings Release (Estimated) Add to calendar
Aug 6, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Call
Aug 5, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -59.40% -525.04%
Operating margin -20.26% -502.34%
EBITD margin - -407.84%
Return on average assets -9.68% -43.52%
Return on average equity -61.05% -150.79%
Employees 19 -
CDP Score - -


2486 Dunwin Drive
+1-416-6790771 (Phone)

Website links


Acerus Pharmaceuticals Corp, formerly Trimel Pharmaceuticals Corp, is a pharmaceutical company that focuses on the development, manufacture, marketing and distribution of products with a focus in men's health and women's health. The Company's products include Natesto, which is nasal testosterone replacement therapy that is developed for the treatment of male hypogonadism (Low T); Estrace, which is an oral 17-beta estradiol tablet used for the symptomatic relief of menopausal symptoms, and Tefina, which is a low-dose nasal testosterone gel that is developed for the treatment of female orgasmic disorder. The Company's Tefina product has completed its Phase II clinical trial. The Company holds a license for the development and marketing rights of its products utilizing a bio adhesive intranasal gel drug delivery technology platform, and owns a unit-dose dry powder inhaler/nasal dispersion system, TriVair.

Officers and directors

Ian O. Ihnatowycz Independent Chairman of the Board
Age: 61
Tom Rossi President, Chief Executive Officer, Director
Michael Bumby Chief Financial Officer
Age: 50
Matthew Hawkins Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson Vice President - Scientific Affairs
Rolf K. Reininghaus Executive Director, Director
Stephen Robert Gregory Lead Independent Director
Norma Beauchamp Director
Matthew Jonathan Pfeffer CPA Independent Director
Age: 57
Jeffrey D. Sherman Independent Director